Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tagamet HB 200 Liquid

This article was originally published in The Tan Sheet

Executive Summary

National TV advertising breaks June 5 for first OTC liquid H2 antagonist. SmithKline Beecham's Tagamet HB extension launched in April (1"The Tan Sheet" May 15, p. 4). FSIs with a $2-off coupon for any size liquid and a $1 coupon for 12-count tablets will continue to be distributed throughout the year, accompanied by in-store promotions and $5 rebate coupons available with product on retail shelves, SB says. Product employs an accordion-style label in order to fit all necessary instructions and warnings (2"The Tan Sheet" July 19, 1999, p. 5)

You may also be interested in...



Aquafresh Gum, Lozenges Carry "For Oral Care - Anytime, Anywhere" Tagline

SmithKline Beecham is moving its Aquafresh brand beyond the traditional dentrifice category into what appears to be the confectionary market.

Tagamet HB 200 Suspension Safety Data In Children Requested By FDA

FDA has asked SmithKline Beecham to conduct a "pharmacodynamic/safety study in pediatric subjects less than 12 years of age, if such data are not available," for Tagamet HB 200 suspension. The suspension form of the H2 antagonist cimetidine was approved July 9. SmithKline submitted NDA 20-951 Dec. 29, 1997.

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

PS091288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel